

Amendments to the claims

1. (Original) A method for treating ischemic heart diseases, which comprises the step of administering angiopoietin-1 or a vector encoding angiopoietin-1.

2. (Original) The method for treating ischemic heart diseases according to claim 1, which comprises the step of administering angiopoietin-1 or a vector encoding angiopoietin-1, and in which a vascular endothelial growth factor is not administered.

3. (Currently Amended) The method according to claim 1 or 2, wherein ~~angiopoietin-1 or the vector encoding angiopoietin-1 is a viral vector encoding~~ angiopoietin-1.

4. (Original) The method according to claim 3, wherein the viral vector is an adenoviral vector.

5. (Original) The method according to claim 3, wherein the viral vector is a minus-strand RNA viral vector.

6. (Currently Amended) The method according to claim 1 or 2, wherein ~~angiopoietin-1 or the vector encoding angiopoietin-1 is a naked DNA.~~

7. (Currently Amended) The method according to any one of claims 1 to 6, wherein ~~angiopoietin-1~~ or the vector encoding angiopoietin-1 is a vector that drives angiopoietin-1 expression using a CA promoter or a promoter having a transcriptional activity equivalent to or higher than that of said CA promoter.

8. (Original) The method according to any one of claims 1 to 7, wherein the administration of angiopoietin-1 or the vector encoding angiopoietin-1 is an injection into cardiac muscle.

9. (Original) A method for treating ischemic diseases, which comprises the step of administering a viral vector encoding angiopoietin-1.

10. (Original) The method for treating ischemic diseases according to claim 9, which comprises the step of administering a viral vector encoding angiopoietin-1, and wherein a vascular endothelial growth factor is not administered.

11. (Original) The method according to claim 9 or 10, wherein the viral vector is an adenoviral vector.

12. (Original) The method according to claim 9 or 10, wherein the viral vector is a minus-strand RNA viral vector.

13. (Original) The method according to any one of claims 9 to 12, wherein the vector administration is an injection into an ischemic site.

14. (Original) A genetically modified mesenchymal cell comprising a foreign gene encoding angiopoietin-1.

15. (Original) The mesenchymal cell according to claim 14, into which an adenoviral vector encoding angiopoietin-1 has been introduced.

16. (Original) The mesenchymal cell according to claim 14, into which a minus-strand RNA viral vector encoding angiopoietin-1 has been introduced.

17. (Original) A therapeutic composition for ischemia, which comprises the mesenchymal cell according to any one of claims 14 to 16 and a pharmaceutically acceptable carrier.

18. (Original) A method for producing a genetically modified mesenchymal cell, wherein the method comprises the step of contacting the mesenchymal cell with a minus-strand RNA viral vector carrying a gene.

19. (Original) The method according to claim 18, wherein the gene encodes angiopoietin-1.